According to DelveInsight’s latest analysis, Nipocalimab is expected to capture meaningful market share across both prevalent ...

Dengue comes with fever, body pain, and a whole lot of confusion, especially when it comes to treatment. The moment someone ...

Researchers sought to determine whether combining enasidenib with venetoclax would be effective in patients with IDH2-mutated ...

Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025Autolus ...

As of Friday, January 09, Rigel Pharmaceuticals, Inc.’s RIGL share price has dipped by 5.01%, which has investors questioning ...

The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...

The European regulator’s anniversary year featured first-in-class therapies, rare-disease advances, safety warnings, and new ...

Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reports ...